Abstract:Background: Melanoma is a heterogeneous malignancy. We set out to identify the molecular underpinnings of high-risk melanomas, those that are likely to progress rapidly, metastasize, and result in poor outcomes. Methods: We examined transcriptome changes from benign states to early-, intermediate-, and late-stage tumors using a set of 78 treatment-naive melanocytic tumors consisting of primary melanomas of the skin and benign melanocytic lesions. We utilized a next-generation sequencing platform that enabled a comprehensive analysis of protein-coding and -noncoding RNA transcripts. Results: Gene expression changes unequivocally discriminated between benign and malignant states, and a dual epigenetic and immune signature emerged defining this transition. To our knowledge, we discovered previously unrecognized melanoma subtypes. A high-risk primary melanoma subset was distinguished by a 122-epigenetic gene signature ("epigenetic" cluster) and TP53 family gene deregulation (TP53, TP63, and TP73). This subtype associated with poor overall survival and showed enrichment of cell cycle genes. Noncoding repetitive element transcripts (LINEs, SINEs, and ERVs) that can result in immunostimulatory signals recapitulating a state of "viral mimicry" were significantly repressed. The high-risk subtype and its poor predictive characteristics were validated in several independent cohorts. Additionally, primary melanomas distinguished by specific immune signatures ("immune" clusters) were identified. Conclusion: The TP53 family of genes and genes regulating the epigenetic machinery demonstrate strong prognostic and biological relevance during progression of early disease. Gene expression profiling of protein-coding and -noncoding RNA transcripts may be a better predictor for disease course in melanoma. This study outlines the transcriptional interplay of the cancer cell's epigenome with the immune milieu with potential for future therapeutic targeting. Funding: National Institutes of Health (CA154683, CA158557, CA177940, CA087497-13), Tisch Cancer Institute, Melanoma Research Foundation, the Dow Family Charitable Foundation, and the Icahn School of Medicine at Mount Sinai.

Differential histone acetylation and super-enhancer regulation underlie melanoma cell dedifferentiation

FADS2-mediated fatty acid desaturation and cholesterol esterification are signatures of metabolic reprogramming during melanoma progression

DNA promoter hypermethylation of melanocyte lineage genes determines melanoma phenotype

Transcriptional dissection of melanoma identifies a high-risk subtype underlying TP53 family genes and epigenome deregulation

ZEB1 controls a lineage-specific transcriptional program essential for melanoma cell state transitions

Enhancer methylation dynamics contribute to cancer plasticity and patient mortality

Ex vivo mapping of enhancer networks that define the transcriptional program driving melanoma metastasis

The utility of DNA methylation profiling in the diagnosis of un-, de- and trans-differentiated melanoma: a series of 11 cases

Specific SOX10 enhancer elements modulate phenotype plasticity and drug resistance in melanoma

The clinicopathologic spectrum and genomic landscape of de-/trans-differentiated melanoma

ALDH1A3-acetaldehyde metabolism potentiates transcriptional heterogeneity in melanoma

The MITF regulatory network in melanoma

Histone deacetylases, Mbd3/NuRD, and Tet2 hydroxylase are crucial regulators of epithelial-mesenchymal plasticity and tumor metastasis

Transcriptional switches in melanoma T Cells: Facilitating polarizing into regulatory T cells

Multi-modal molecular programs regulate melanoma cell state

Lysosomal acid ceramidase ASAH1 controls the transition between invasive and proliferative phenotype in melanoma cells

Melanoma Differentiation Trajectories Determine Sensitivity toward Pre-Existing CD8D Tumor

Epigenetic silencing of TET2 and TET3 induces an EMT-like process in melanoma

The Janus-faced Role of KDM5B Heterogeneity in Melanoma: Differentiation As a Situational Driver of Both Growth Arrest and Drug-Resistance

Functional specialization of MITF, TFEB and TFE3 drives radically distinct adaptive gene expression programs in melanoma.

Sequential transcriptional waves and NF-κB-driven chromatin remodeling direct drug-induced dedifferentiation in cancer